---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-079774"
form_type: "8-K"
ticker: "RMTI"
cik: "0001041024"
company_name: "ROCKWELL MEDICAL, INC."
filed_at: "2023-07-11T23:59:59+00:00"
generated_at: "2026-06-13T09:46:05.526384+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Rockwell Medical acquires Evoqua hemodialysis concentrates business for $16M total consideration

## Summary
- Acquisition for $11M cash at closing plus two $2.5M installments at 12 and 24 months.
- Funded from cash; post-close cash was $15.3M.
- Acquired business generated ~$18M trailing revenue and >$3.3M EBITDA.
- 2023 revenue guidance raised to $82-86M from prior expectation.
- Preliminary Q2 2023 revenue $18.0-18.3M, net loss per share pro forma $(1.31) for FY 2022.

## SEC filing metadata
- accession: 0001104659-23-079774
- form_type: 8-K
- ticker: RMTI
- cik: 0001041024
- company_name: ROCKWELL MEDICAL, INC.
- filed_at: 2023-07-11T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 2.02, 8.01, 3.02, 3.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1041024/000110465923079774/0001104659-23-079774-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1041024/000110465923079774/tm2320979d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-079774
- JSON: https://secwatch.observer/filing/0001104659-23-079774.json
- Plain text: https://secwatch.observer/filing/0001104659-23-079774.txt

## Key facts
- Earnings Releases
  ROCKWELL MEDICAL, INC. reported 2023 results: revenue between $82.0 million and $86.0 million. Guidance raised.
  - Period: 2023
  - Revenue: between $82.0 million and $86.0 million
  - Guidance: raised
  - Result: guidance update
  source text: Rockwell Medical increases its 2023 revenue guidance to between $82.0 million and $86.0 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1041024/000110465923079774/0001104659-23-079774-index.htm
- Material Agreements
  ROCKWELL MEDICAL, INC. entered into Asset Purchase Agreement with Evoqua Water Technologies LLC valued at $11,000,000 in cash paid at Closing and equal annual installments of $2,500,000 (effective 2023-07-10).
  - Action: entry
  - Agreement: asset purchase
  - Counterparty: Evoqua Water Technologies LLC
  - Value: $11,000,000 in cash paid at Closing and equal annual installments of $2,500,000
  - Effective: 2023-07-10
  source text: On July 10, 2023, Rockwell Medical, Inc. (the “Company”) executed and consummated the transactions contemplated by an Asset Purchase Agreement (the “Purchase Agreement”) with Evoqua Water Technologies LLC, a Delaware limited liability company (“Evoqua”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1041024/000110465923079774/0001104659-23-079774-index.htm
- Material Agreements
  ROCKWELL MEDICAL, INC. entered into Letter Agreement with Armistice Capital Master Fund Ltd. valued at approximately $13.8 million (effective 2023-07-10).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: Armistice Capital Master Fund Ltd.
  - Value: approximately $13.8 million
  - Effective: 2023-07-10
  source text: On July 10, 2023, the Company entered into a letter agreement (the “Letter Agreement”) with Armistice Capital Master Fund Ltd. (“Armistice”), which held a warrant (the “Prior Warrant”) to purchase 9,900,990 shares of common stock of the Company (the “Common Stock”) with an exercise price of $1.39 per share, offering Armistice the opportunity to exercise the Prior Warrant for cash, provided the Prior Warrant was exercised for cash on or prior to 5:00 P.M. Eastern Time on July 10, 2028 (the “End Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1041024/000110465923079774/0001104659-23-079774-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.